A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

Inclusion Criteria:

   - Body mass index of 18 - 36 kg/m^2 and body weight ≥45 kg

   - HBeAg ≥500 IU/mL at Screening

   - In good general health except for chronic HBV infection for ≥6 months documented, for
   example, by at least two measurements of HBsAg positivity and/or detectable HBV DNA ≥6
   months apart

   - Lack of cirrhosis or advanced liver disease

Exclusion Criteria:

   - Prior treatment for chronic HBV infection with lamivudine, telbivudine, adefovir,
   standard of care nucleoside or nucleotide analogue (NrtI), HBV core inhibitors, or an
   investigational agent for HBV infection

   - History or evidence of advanced liver disease or hepatic decompensation (including
   jaundice, ascites, portal hypertension, gastrointestinal bleeding, esophageal varices,
   hepatic encephalopathy)

   - History or presence of clinically significant medical conditions requiring frequent
   medical management or pharmacologic or surgical treatment